Cardio Diagnostics’ (CDIO) “Speculative Buy” Rating Reiterated at Benchmark

Benchmark reissued their speculative buy rating on shares of Cardio Diagnostics (NASDAQ:CDIO) in a research note published on Tuesday, Benzinga reports. Benchmark currently has a $2.00 target price on the stock.

Cardio Diagnostics Stock Performance

Shares of Cardio Diagnostics stock opened at $0.38 on Tuesday. The firm’s 50 day simple moving average is $0.48 and its two-hundred day simple moving average is $0.86. Cardio Diagnostics has a 12-month low of $0.17 and a 12-month high of $3.56.

Cardio Diagnostics (NASDAQ:CDIO) last released its earnings results on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.07. Cardio Diagnostics had a negative return on equity of 415.33% and a negative net margin of 34,911.87%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.13 million. Sell-side analysts anticipate that Cardio Diagnostics will post -0.55 earnings per share for the current year.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.